Arancha Cebrián (Arancha Cebrián Aranda)

ORCID

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 17

Top Venues

British journal of cancer

Pharmaceutics

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Anxo Río-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A Mateos-Gómez, Marina I Schlaepfer, Laura Del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero, Juan Carlos Lacal, Enzo Medico, Jesús García-Foncillas, Arancha Cebrián
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. British journal of cancer 130 (8) (2024)
Anxo Río-Vilariño, Jesús García-Foncillas, Arancha Cebrián
Reply to Dr. Rafael Rosell: Shedding some light on the unresolved issue of YAP1 Ser397 phosphorylation in cancer. British journal of cancer 131 (3) (2024)
Anxo Río-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A Mateos-Gómez, Marina I Schlaepfer, Laura Del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero, Juan Carlos Lacal, Enzo Medico, Jesús García-Foncillas, Arancha Cebrián
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. British journal of cancer (2024)
Anxo Río-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A Mateos-Gómez, Marina I Schlaepfer, Laura Del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero, Juan Carlos Lacal, Enzo Medico, Jesús García-Foncillas, Arancha Cebrián
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. British journal of cancer (2024)
Anxo Río-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A Mateos-Gómez, Marina I Schlaepfer, Laura Del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero, Juan Carlos Lacal, Enzo Medico, Jesús García-Foncillas, Arancha Cebrián
Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. British journal of cancer (2024)
Anxo Río-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A Mateos-Gómez, Marina I Schlaepfer, Laura Del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero, Juan Carlos Lacal, Enzo Medico, Jesús García-Foncillas, Arancha Cebrián
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. British journal of cancer 130 (8) (2024)
Anxo Río-Vilariño, Jesús García-Foncillas, Arancha Cebrián
Reply to Dr. Rafael Rosell: Shedding some light on the unresolved issue of YAP1 Ser397 phosphorylation in cancer. British journal of cancer 131 (3) (2024)
Anxo Río-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A Mateos-Gómez, Marina I Schlaepfer, Laura Del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero, Juan Carlos Lacal, Enzo Medico, Jesús García-Foncillas, Arancha Cebrián
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. British journal of cancer 130 (8) (2024)
Anxo Río-Vilariño, Jesús García-Foncillas, Arancha Cebrián
Reply to Dr. Rafael Rosell: Shedding some light on the unresolved issue of YAP1 Ser397 phosphorylation in cancer. British journal of cancer (2024)
Anxo Río-Vilariño, Jesús García-Foncillas, Arancha Cebrián
Reply to Dr. Rafael Rosell: Shedding some light on the unresolved issue of YAP1 Ser397 phosphorylation in cancer. British journal of cancer 131 (3) (2024)
Anxo Río-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A Mateos-Gómez, Marina I Schlaepfer, Laura Del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero, Juan Carlos Lacal, Enzo Medico, Jesús García-Foncillas, Arancha Cebrián
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. British journal of cancer (2024)
Anxo Río-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A Mateos-Gómez, Marina I Schlaepfer, Laura Del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero, Juan Carlos Lacal, Enzo Medico, Jesús García-Foncillas, Arancha Cebrián
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. British journal of cancer 130 (8) (2024)
Anxo Río-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A Mateos-Gómez, Marina I Schlaepfer, Laura Del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero, Juan Carlos Lacal, Enzo Medico, Jesús García-Foncillas, Arancha Cebrián
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. British journal of cancer 130 (8) (2024)
Anxo Río-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A Mateos-Gómez, Marina I Schlaepfer, Laura Del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero, Juan Carlos Lacal, Enzo Medico, Jesús García-Foncillas, Arancha Cebrián
Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. British journal of cancer (2024)
Anxo Río-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A Mateos-Gómez, Marina I Schlaepfer, Laura Del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero, Juan Carlos Lacal, Enzo Medico, Jesús García-Foncillas, Arancha Cebrián
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. British journal of cancer 130 (8) (2024)
Juan Carlos Lacal, Rosario Perona, Javier de Castro, Arancha Cebrián
Choline Kinase α Inhibitors MN58b and RSM932A Enhances the Antitumor Response to Cisplatin in Lung Tumor Cells. Pharmaceutics 14 (6) (2022)
Barbara Manzanares-Martin, Arancha Cebrián, Laura Del Puerto-Nevado, Rafael González, Sonia Solanes, Maria Auxiliadora Gómez-España, Jesús García-Foncillas, Enrique Aranda
Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes. Journal for immunotherapy of cancer 9 (4) (2021)

Arancha Cebrián.css-eqlu8i{font-size:small;padding-left:4px;} (Arancha Cebrián Aranda)

Publication Activity (10 Years)

Top Topics

Top Venues

Arancha Cebrián (Arancha Cebrián Aranda)